

POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 35 / 2021

Date of preparation: 2021-04-29
Abbreviated name of the Issuer: MABION S.A.

Subject matter: Conclusion of an annex to the cooperation agreement with Mylan Ireland Ltd.

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to the information provided in current and periodic reports regarding the cooperation of Mabion S.A. ("Company") with Mylan Ireland Ltd. ("Mylan"), the Management Board of the Company hereby informs that on 29 April 2021, it signed an annex ("Annex") to the cooperation agreement ("Agreement", i.e. Development and Commercialization Agreement) with Mylan, of which the Company informed in Current Report no. 31/2016 of 8 November 2016.

Under the Annex, the Parties agreed that Mylan will remain the Company's non-exclusive distribution partner for MabionCD20 in selected countries in regions including Australia, New Zealand, Mexico, Central America, southern Africa and south-eastern Asia. At the same time, it was decided that Mylan's exclusive right to sell MabionCD20 in the European Union and the Balkans, as well as Mylan's priority right to enter into a commercialisation agreement for MabionCD20 in the United States (USA), shall expire.

The change in the scope of cooperation with Mylan will enable the Company to acquire a new partner or partners interested in commercialising MabionCD20 on the European and American markets and to engage in cooperation taking into account the potential of MabionCD20 and the current market conditions. In addition, the Annex in force does not affect the Company's current activities aimed at obtaining the marketing authorisation for MabionCD20 from the European Medicines Agency, or their schedule.

At the same time, the Parties agreed that the Company will reimburse to Mylan part of the received advance payments in an amount lower than the amount of the payments received by the Company under the Agreement before the date of the Annex and constituting repayable advances for distribution rights, which shall be tantamount to the final settlement of all payments made so far between the Parties. As a consequence of signing the Annex, the Company has obtained the necessary flexibility in the commercialisation of MabionCD20 in its key markets in Europe and in the United States (USA).